United States Food and Drug Administration approval summary: Bortezomib for the treatment of progressive multiple myeloma after one prior therapy

Clinical Cancer Research

Volumn 12, Issue 10, 2006, Pages 2955-2960

  Kane, Robert C ^a   Farrell, Ann T ^a   Sridhara, Rajeshwari ^a   Pazdur, Richard ^a  

^a CENTER FOR DRUG EVALUATION AND RESEARCH   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

BORTEZOMIB; DEXAMETHASONE;

ABDOMINAL PAIN; ADULT; AGED; ANEMIA; ANOREXIA; APPETITE DISORDER; ARTICLE; ASTHENIA; CANCER CHEMOTHERAPY; CANCER GROWTH; CANCER SURVIVAL; CARDIOGENIC SHOCK; CLINICAL TRIAL; CONGESTIVE HEART FAILURE; CONSTIPATION; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; COUGHING; DIARRHEA; DOSE RESPONSE; DRUG APPROVAL; DRUG EFFICACY; DRUG MEGADOSE; DRUG SAFETY; DYSESTHESIA; DYSPNEA; FEVER; FOOD AND DRUG ADMINISTRATION; HEADACHE; HEART ARREST; HUMAN; HYPERCALCEMIA; HYPERGLYCEMIA; INSOMNIA; LOWER RESPIRATORY TRACT INFECTION; LUNG INFECTION; MAJOR CLINICAL STUDY; MENTAL DISEASE; MULTIPLE MYELOMA; NAUSEA; NEUTROPENIA; PARESTHESIA; PERIPHERAL NEUROPATHY; PHASE 3 CLINICAL TRIAL; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; RASH; RESPIRATORY FAILURE; SINGLE BLIND PROCEDURE; THROMBOCYTOPENIA; TREATMENT RESPONSE; UNITED STATES; UNSPECIFIED SIDE EFFECT; VOMITING;

AGED; ANTINEOPLASTIC AGENTS; BORONIC ACIDS; CLINICAL TRIALS, PHASE III; DEXAMETHASONE; DISEASE PROGRESSION; DRUG APPROVAL; FEMALE; HUMANS; MALE; MIDDLE AGED; MULTICENTER STUDIES; MULTIPLE MYELOMA; PYRAZINES; RANDOMIZED CONTROLLED TRIALS; SURVIVAL ANALYSIS; UNITED STATES; UNITED STATES FOOD AND DRUG ADMINISTRATION;

EID: 33744832401     PISSN: 10780432     EISSN: None     Source Type: Journal    
DOI: 10.1158/1078-0432.CCR-06-0170     Document Type: Article

References (9)

1. Johnson JR, Temple R. Food and Drug Administration requirements for approval of anticancer drugs. Cancer Treat Rep 1985;69:1155-9.
2. Johnson JR, Williams G, Pazdur R. End points and United States Food and Drug Administration approval of oncology drugs. J Clin Oncol 2003;21: 1404-11.
3. Brass PF, Kane RC, Farrell AT, et al. Approval summary for bortezomib for injection in the treatment of multiple myeloma. Clin Cancer Res 2004; 10:3954-64.
4. Alexanian R, Barlogie B, Dixon D. High-dose glucocorticoid treatment of resistant myeloma. Ann Intern Med 1986;105:8-11.
5. Buzaid AC, Durie BG. Management of refractory myeloma: a review. J Clin Oncol 1988;6:889-905.
6. Durie BG, Kyle RA, Belch A, et al. Myeloma management guidelines: a consensus report from the scientific advisors of the international myeloma foundation. Hematol J 2003;4:379-98.
7. Bladé J, Samson D, Reece D, et al. Criteria for evaluating disease response and progression in patients with multiple myeloma treated by high-dose therapy and haemopoietic stem cell transplantation. Myeloma Subcommittee of the EBMT. European Group for Blood and Marrow Transplant. Br J Haematol 1998;102:1115-23.
8. Kane RC, Bross PF, Farrell AT, Pazdur R, Velcade: U.S. FDA approval for the treatment of multiple myeloma progressing on prior therapy. Oncologist 2003;8: 508-13.
9. Durie BGM, Jacobson J, Barlogie B, Crowley J. Time to first progression, but not magnitude of regression predicts survival benefit in SWOG standard dose chemotherapy studies for multiple myeloma. J Clin Oncol 2004;22:1857-63.